| February 2 |
Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease, According to New Study |
| February 2 |
Unigene Clinical Study Suggests Novel Treatment Regimen for Osteoporosis |
| February 2 |
Ligand Announces Phase IIb Results With DARA |
| February 2 |
Hospira's Precedex Phase IV Study Published in the Journal of the American Medical Association |
| February 2 |
Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease |
| February 2 |
Newer Medication May Offer Advantages Over Agents Commonly Used For Sedation of Intensive Care Unit Patients |
| February 3 |
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF |
| February 3 |
Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer |
| February 3 |
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3 |
| February 3 |
Merck’s Safinamide Significantly Improved Motor Function in Patients with Advanced Parkinson’s Disease in a Phase III Pivotal Trial |
| February 3 |
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant |
| February 3 |
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results |
| February 3 |
Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate |
| February 3 |
Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease |
| February 3 |
Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine |
| February 3 |
PhytoMedical's Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer |
| February 3 |
AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences |
| February 4 |
Allos Therapeutics Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma |
| February 4 |
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer |
| February 4 |
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study |
| February 4 |
Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository |
| February 4 |
GSK and Theravance Announce Positive Phase 2b Results for Once-daily Fluticasone Furoate in the Treatment of Asthma |
| February 4 |
Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis |
| February 5 |
New Evidence of Hormone Therapy Causing Breast Cancer, Stanford Professor Says |
| February 5 |
BioDelivery Sciences Announces Initial Results of Phase 1 Clinical Study of Bioral Amphotericin B |
| February 5 |
Interim Results From the MIRACEL Study Now Reported In the Renal Anaemia Disease Knowledge Centre at EPG Online |
| February 5 |
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients |
| February 5 |
Physicians from the Burzynski Clinic Present Initial Results of Combination Gene-Targeting Therapies on Advanced Pancreatic and Liver Cancers |
| February 5 |
Minocycline/Rifampin-Impregnated Catheters Proven Clinically Effective in Preventing and Combating Potentially Fatal Bloodstream Infections in Two New Studies |
| February 5 |
HemCon Medical Technologies, Inc. Announces Promising Results from Live Nail Infection Anti-Fungal Study Technology Platform Offers Tested Solution to Fungal Care Market |
| February 6 |
Bioalliance Pharma Presents Results on a New Quinoline Family on HIV Integrase Inhibitors at the 16Th Conference on Retroviruses and Opportunistic Infections (CROI) |
| February 9 |
M. D. Anderson Study Finds Pregnancy Has No Impact on Breast Cancer Survival, Does Delay Treatment, Diagnosis |
| February 9 |
Benitec Limited (ASX:BLT) City of Hope Human HIV Trial Update |
| February 9 |
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study |
| February 9 |
Anti-HIV Gel Shows Promise in Large-Scale Study in Women |
| February 9 |
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients |
| February 9 |
MS Patients Treated with Tysabri Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology |
| February 9 |
EntreMed Presents Initial Clinical Results for ENMD-2076 |
| February 9 |
New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide |
| February 9 |
Winston Pharmaceuticals Announces Positive Top-line Results of Phase I Clinical Trial of Civamide Patch |
| February 9 |
Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology |
| February 10 |
ConjuChem reports final data confirming PC-DAC:Exendin-4 lowers glucose and weight in Phase II diabetes trials |
| February 10 |
Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result |
| February 10 |
Theratechnologies presents data at CROI |
| February 10 |
Phase III Studies Showed Isentress in Combination Therapy Provided Significant Viral Load Reductions Through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIV |
| February 10 |
Data from Isentress, Merck's HIV Integrase Inhibitor, in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16th Conference on Retroviruses and Opportunistic Infections |
| February 10 |
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) |
| February 10 |
Study Demonstrates Restylane Effect Lasted 18 Months in 97% of Patients With One Repeat Injection |
| February 10 |
Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic |
| February 11 |
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study |
| February 11 |
Regenocyte Therapeutic Reports Successful Treatment of Cardiomyopathy with Stem Cells |
| February 11 |
CLSI Publishes Guideline for Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data |
| February 11 |
Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results |
| February 11 |
Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder |
| February 12 |
La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial |
| February 12 |
Zometa Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports |
| February 12 |
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile |
| February 12 |
Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium |
| February 12 |
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq (dronedarone) in Atrial Fibrillation |
| February 12 |
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction |
| February 12 |
GenoMed's Results Supported by Canadian Study: Dose is Key! |
| February 12 |
Hope for 14 Million Rosacea Sufferers: Pyratine-XR Study to be Presented at South Beach Symposium |
| February 12 |
Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire |
| February 12 |
Promising medical news for atrial fibrillation patients |
| February 13 |
Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting |
| February 13 |
Study Reveals Avosentan May Slow Progression of Diabetic Kidney Disease |
| February 17 |
Update of Long-Term Data on Brain Cancer Patients Receiving DCVax-Brain Continues to Show Striking Improvements in Delay of Disease and Survival |
| February 17 |
IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients |
| February 17 |
Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity |
| February 17 |
BioSante Pharmaceuticals, Inc. Presents LibiGel Clinical and Market Information at ISSWSH Conference |
| February 17 |
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference |
| February 17 |
Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease |
| February 17 |
Pluristem Therapeutics to Present at Italian CREM Workshop Focused on Placental-Derived Cells |
| February 17 |
Newly Published Menopause Study: 'Bioidentical' and FDA-Approved Divigel (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause |
| February 17 |
University of Ottawa Heart Institute Scientists Unlock Mechanism That Turns on Weight-Loss Gene |
| February 17 |
Transgene Confirms Longer Survival For Patients Treated With Tg4010 In Its Ongoing Phase IIb Non-Small Cell Lung Cancer Trial |
| February 17 |
Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009 |
| February 17 |
Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C |
| February 17 |
Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C |
| February 18 |
High-Throughput Genotyping of AML Patients for a Key Immune Receptor May Significantly Improve Treatment Outcome |
| February 18 |
Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology |
| February 18 |
Compared To Standard Therapies, Pixantrone Decreases Time To Achieve Complete Remission By 47% In Relapsed Aggressive Non-Hodgkin's Lymphoma |
| February 18 |
VGX Pharmaceuticals Proprietary DNA Vaccines Delivered with Electroporation Achieve Immune Responses Superior to Recombinant Adenovirus Serotype 5 (Ad5) Vectors |
| February 18 |
Phase III Results in SOFIA Study of NPL-2008 |
| February 18 |
iCo Therapeutics Oral Amphotericin B Published in Leading Journal |
| February 18 |
Lancet Oncology: Epigenetic drug doubles survival in patients with 'preleukemia,' MDS |
| February 18 |
Stanford Scientists Identify Drug to Treat Opioid Addiction |
| February 18 |
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma |
| February 18 |
KanekaQH Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure |
| February 18 |
Data Published in The Lancet Oncology Further Substantiates VIDAZA's Extended Survival Benefit for MDS Patients |
| February 19 |
Research Brings New Hope to Multiple Sclerosis Patients |
| February 19 |
Kidney Disease Affects Response to Blood Thinner |
| February 19 |
New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX Trial |
| February 19 |
Crestor Cuts Risk of Stroke by Nearly Half in JUPITER Study |
| February 20 |
EPIX Pharmaceuticals to Present Preclinical Data for Two Programs at Keystone Symposia |
| February 20 |
ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs |
| February 20 |
Study of Genzyme Oral Compound for Gaucher Disease Meets Primary Endpoint |
| February 20 |
UCB Announces Top-Line Outcomes for Proof-of-Concept Studies |
| February 23 |
Bavarian Nordic A/S (DK) - Bavarian Nordic updates on Phase I/II studies with breast cancer vaccine |
| February 23 |
EpiCept Announces EPC2407 Generic Name is Crinobulin |
| February 23 |
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections |
| February 23 |
Clinical Results with RegeneRx's Ophthalmic Drug Candidate Subject of Oral Presentation at 2009 ARVO Meeting |
| February 23 |
VGX Pharmaceuticals Avian Influenza DNA Vaccine Delivered with Electroporation Provides 100% Protection of Non-Human Primates |
| February 23 |
Data on VELCADE (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop |
| February 24 |
AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints |
| February 24 |
Orion Corporation (FI) - Orion: Primary Objective of STRIDE-PD Study Was Not Achieved |
| February 24 |
Optimer Pharmaceuticals Announces Positive Results from Second Phase 3 Study of Prulifloxacin for Infectious Diarrhea in Travelers |
| February 24 |
Tekmira Presents Data Demonstrating Further Increases in SNALP Potency |
| February 24 |
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints |
| February 24 |
PharmAthene Presents Data for SparVax and Valortim, a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting |
| February 25 |
Adipose-Derived Stem and Regenerative Cells Prevent Mortality and Reduce Kidney Damage in Preclinical Study |
| February 25 |
Bavarian Nordic reports further data on Prostvac |
| February 25 |
Avigen Announces Positive Data for AV411 in Pain Relief and Drug Addiction |
| February 25 |
PharmAthene Anthrax Protection Data Presented at ASM Biodefense Disease Meeting |
| February 25 |
AVEO Pharmaceuticals' Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer |
| February 25 |
Hawaii Biotech Reports Phase 1 Results for West Nile Virus Vaccine |
| February 25 |
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer |
| February 25 |
Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients |
| February 25 |
New Cancer Treatment Stops Aggressive Sarcomas |
| February 25 |
Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients |
| February 26 |
CPEX Pharmaceuticals Announces Completion of Phase 2 Trial for Urology Drug by Serenity Pharmaceuticals |
| February 26 |
Optimer Pharmaceuticals Announces Publication in Peer-Reviewed Journal about Prulifloxacin's Antibacterial Activity against Infectious Diarrhea Producing Bacteria |
| February 26 |
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects |
| February 26 |
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting |
| February 26 |
DeveloGen AG (DE) - DeveloGen Reports Positive Phase 1 Clinical Trial Results for DG3173 |
| February 26 |
RegeneRx Updates on Phase II Venous Stasis Trial |
| February 26 |
Crucell N.V. (NL) - Crucell's Revolutionary Antibody for Universal Therapy Against Flu |
| February 26 |
Reproductive Factors May Protect Women from Parkinson's Disease |
| February 26 |
Research Finding Could Revolutionize Asthma Treatment |
| February 27 |
Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium |
| February 27 |
BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma |
| February 27 |
Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study |
| February 27 |
Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium |
| February 27 |
Mesoblast Limited (ASX:MSB) Presents Positive Adult Stem Cell Results To American Academy of Orthopedic Surgeons (AAOS) |
| February 27 |
Cell Genesys Announces Final Results from Phase 3 Program of GVAX Immunotherapy for Prostate Cancer |
| February 27 |
Cougar Biotechnology Announces Presentation of Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO 2009 Genitourinary Cancers Symposium |
| February 27 |
Data Published in The Lancet Show Fampridine-SR Improved Walking Ability in People with Multiple Sclerosis |
| February 27 |
Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma |
| February 27 |
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer |
